First Gene Editing Cure Shows 87% Attack Reduction in Trial

A single-dose CRISPR treatment freed patients from a painful genetic disorder that causes life-threatening swelling attacks.

The breakthrough marks the first Phase 3 success for in vivo gene editing and could launch in 2027.